{
  "abstract": "Advancement of molecular targeted therapies has revolutionized the treatment of several challenging and previously refractory tumors. Since the introduction of rituximab in 1997, the field of molecular targeted agents have continued to evolve. Notably, vorasidenib, a brainpenetrant dual inhibitor of mutant isocitrate dehydrogenase (IDH) 1 and 2, has recently demonstrated promising results in the 2023 INDIGO trials with improved progression-free survival and delayed need for subsequent interventions in patients with IDH-mutant low-grade gliomas. Although therapeutic options for glioma have long remained largely limited to surgery, radiation, and conventional chemotherapy despite extensive and ongoing research, the advent of vorasidenib opens a new chapter in glioma treatment. This review summarizes the key clinical studies of vorasidenib and discusses its potential role, limitations, and future directions in the evolving treatment paradigm of IDH-mutant gliomas.",
  "abstract_shown": true,
  "affiliations": [
    "Korean Brain Tumor Society, Seoul, Korea",
    "Department of Neurosurgery, Inha University Hospital, Inha University College of Medicine, Incheon, Korea",
    "Department of Neurosurgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea",
    "Department of Neurosurgery, School of Medicine, Kyungpook National University, Daegu, Korea",
    "Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea",
    "Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea",
    "Neuro‑Oncology Clinic, National Cancer Center, Goyang, Korea",
    "Department of Neurosurgery, Dong-A University College of Medicine, Busan, Korea",
    "Department of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea",
    "Department of Neurosurgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea",
    "Department of Neurosurgery, Korea University Anam Hospital, Seoul, Korea"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Kyung-Min Kim",
      "orcid": "0000-0002-1150-3338"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Yukyeng Byeon",
      "orcid": "0000-0003-2970-8259"
    },
    {
      "affs": [
        0,
        3
      ],
      "name": "Chaejin Lee",
      "orcid": "0000-0002-4089-987X"
    },
    {
      "affs": [
        0,
        4
      ],
      "name": "Won‑Jae Lee",
      "orcid": "0000-0003-0653-8568"
    },
    {
      "affs": [
        0,
        5
      ],
      "name": "Kihwan Hwang",
      "orcid": "0000-0001-7211-729X"
    },
    {
      "affs": [
        0,
        6
      ],
      "name": "Yun-Sik Dho",
      "orcid": "0000-0001-5505-0812"
    },
    {
      "affs": [
        0,
        7
      ],
      "name": "Kyoung Su Sung",
      "orcid": "0000-0003-3289-0143"
    },
    {
      "affs": [
        0,
        8
      ],
      "name": "Tae Hoon Roh",
      "orcid": "0000-0002-1004-9364"
    },
    {
      "affs": [
        0,
        4
      ],
      "name": "Kyuha Chong",
      "orcid": "0000-0003-2501-0400"
    },
    {
      "affs": [
        0,
        9
      ],
      "name": "Ki-Su Park",
      "orcid": "0000-0002-4829-6299"
    },
    {
      "affs": [
        0,
        10
      ],
      "name": "Shin-Hyuk Kang",
      "orcid": "0000-0001-9868-2019"
    },
    {
      "affs": [
        0,
        8
      ],
      "name": "Eui Hyun Kim",
      "orcid": "0000-0002-2523-7122"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9bgdwcr6v174n.bib",
  "cited_by": 1,
  "doi": "10.3340/jkns.2026.0113",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13748862/",
  "id": "9bgdwcr6v174n",
  "issns": [
    "2005-3711",
    "1598-7876"
  ],
  "landing_url": "https://doi.org/10.3340/jkns.2026.0113",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Review Article"
    ],
    [
      "heading",
      "Tumor"
    ],
    [
      "openalex",
      "2730|Glioma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7165771751",
  "pdf_url": "https://www.jkns.or.kr/upload/pdf/jkns-2026-0113.pdf",
  "pmcid": "PMC13748862",
  "pmid": "42342239",
  "published": "2026-06-24",
  "publisher": "The Korean Neurosurgical Society",
  "ris": "https://research.draconitic.com/paper/9bgdwcr6v174n.ris",
  "sources": [
    {
      "first_seen": "2026-11-13T12:26:56Z",
      "native_id": "PMC13748862",
      "source": "pmc",
      "url": "https://doi.org/10.3340/jkns.2026.0113"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Glioma Diagnosis and Treatment",
      "subfield": "oncology"
    }
  ],
  "title": "Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology",
  "title_text": "Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology",
  "type": "peer-reviewed",
  "updated_at": "2026-11-13T12:26:56Z",
  "url": "https://research.draconitic.com/paper/9bgdwcr6v174n",
  "venue": "Journal of Korean Neurosurgical Society",
  "versions": []
}